The study also showed that the antitumor immune response triggered by AGuIX and RT was heavily dependent on CD8+ T-cells, as depleting CD8+ T-cells with anti-CD8 antibodies eliminated the combined treatment’s efficacy, both in terms of survival and tumor volume. The gene discussed is CD8A; the disease is neoplasm.